Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David A Hollander

Showing results (21-30 of 76) with videos related to

Pageof 8
Sort By:
Archives of Ophthalmology (Chicago, Ill. : 1960)|February 16, 2005
Macular schisis detachment associated with angle-closure glaucomaDavid A Hollander, Michael E Barricks, Jacque L Duncan, et al.
American Journal of Ophthalmology|June 10, 2008
Ahmed valve implantation with adjunctive mitomycin C and 5-fluorouracil: long-term outcomesJorge A Alvarado, David A Hollander, Richard P Juster, et al.
Ocular Immunology and Inflammation|June 6, 2020
Efficacy of Alcaftadine 0.25% (AGN-229666) for Once-daily Prevention of Cedar-Pollen Allergic Conjunctivitis: A Phase 3 Randomized StudyHiroshi Fujishima, Tomoko Hasunuma, Tetsuya Kawakita, et al.
Ocular Immunology and Inflammation|March 16, 2018
Alcaftadine 0.25% versus Olopatadine 0.1% in Preventing Cedar Pollen Allergic Conjunctivitis in Japan: A Randomized StudyHiroshi Nakatani, Paul Gomes, Ron Bradford, et al.
BMC Ophthalmology|May 27, 2005
Primary graft failure associated with epithelial downgrowth: a case reportAnthony J Aldave, David A Hollander, Bruno Branco, et al.
Therapeutics and Clinical Risk Management|August 17, 2011
Demonstration of an online tool to assist managed care formulary evidence-based decision making: meta-analysis of topical prostaglandin analog efficacySteven M Kymes, Caroline Burk, Todd Feinman, et al.
Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics|June 26, 2010
Ocular surface tolerability of prostaglandin analogs in patients with glaucoma or ocular hypertensionJess T Whitson, William B Trattler, Cynthia Matossian, et al.
Clinical Ophthalmology (Auckland, N.Z.)|April 8, 2014
Bimatoprost 0.01% or 0.03% in patients with glaucoma or ocular hypertension previously treated with latanoprost: two randomized 12-week trialsJonathan S Myers, Steven Vold, Fiaz Zaman, et al.
Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics|May 18, 2011
Intraocular pressure elevations with loteprednol etabonate: a retrospective chart reviewRajesh K Rajpal, Donald Digby, Gerard D'Aversa, et al.
Clinical Ophthalmology (Auckland, N.Z.)|December 11, 2012
PERSIST: Physician's Evaluation of Restasis(®) Satisfaction in Second Trial of topical cyclosporine ophthalmic emulsion 0.05% for dry eye: a retrospective reviewFrancis Mah, Mark Milner, Samuel Yiu, et al.
Pageof 8

Showing results (21-30 of 76) with videos related to

Sort By:
Pageof 8
Archives of Ophthalmology (Chicago, Ill. : 1960)|February 16, 2005
Macular schisis detachment associated with angle-closure glaucomaDavid A Hollander, Michael E Barricks, Jacque L Duncan, et al.
American Journal of Ophthalmology|June 10, 2008
Ahmed valve implantation with adjunctive mitomycin C and 5-fluorouracil: long-term outcomesJorge A Alvarado, David A Hollander, Richard P Juster, et al.
Ocular Immunology and Inflammation|June 6, 2020
Efficacy of Alcaftadine 0.25% (AGN-229666) for Once-daily Prevention of Cedar-Pollen Allergic Conjunctivitis: A Phase 3 Randomized StudyHiroshi Fujishima, Tomoko Hasunuma, Tetsuya Kawakita, et al.
Ocular Immunology and Inflammation|March 16, 2018
Alcaftadine 0.25% versus Olopatadine 0.1% in Preventing Cedar Pollen Allergic Conjunctivitis in Japan: A Randomized StudyHiroshi Nakatani, Paul Gomes, Ron Bradford, et al.
BMC Ophthalmology|May 27, 2005
Primary graft failure associated with epithelial downgrowth: a case reportAnthony J Aldave, David A Hollander, Bruno Branco, et al.
Therapeutics and Clinical Risk Management|August 17, 2011
Demonstration of an online tool to assist managed care formulary evidence-based decision making: meta-analysis of topical prostaglandin analog efficacySteven M Kymes, Caroline Burk, Todd Feinman, et al.
Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics|June 26, 2010
Ocular surface tolerability of prostaglandin analogs in patients with glaucoma or ocular hypertensionJess T Whitson, William B Trattler, Cynthia Matossian, et al.
Clinical Ophthalmology (Auckland, N.Z.)|April 8, 2014
Bimatoprost 0.01% or 0.03% in patients with glaucoma or ocular hypertension previously treated with latanoprost: two randomized 12-week trialsJonathan S Myers, Steven Vold, Fiaz Zaman, et al.
Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics|May 18, 2011
Intraocular pressure elevations with loteprednol etabonate: a retrospective chart reviewRajesh K Rajpal, Donald Digby, Gerard D'Aversa, et al.
Clinical Ophthalmology (Auckland, N.Z.)|December 11, 2012
PERSIST: Physician's Evaluation of Restasis(®) Satisfaction in Second Trial of topical cyclosporine ophthalmic emulsion 0.05% for dry eye: a retrospective reviewFrancis Mah, Mark Milner, Samuel Yiu, et al.
Pageof 8